HARVARD BIOSCIENCE INC - 8-K Filing
Harvard Bioscience reported Q1 2026 revenue of $20.8 million and a gross margin of 59%, up from 56% in the prior year quarter. The company posted a net loss of $3.4 million compared to $(50.3) million last year, which included a goodwill impairment charge. Adjusted EBITDA was flat at $0.8 million for both periods. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $HBIO